Author: Kattan, Joseph; Kattan, Clarisse; Assi, Tarek
Title: Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection? Cord-id: 41cqkmra Document date: 2020_4_15
ID: 41cqkmra
Snippet: The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper
Document: The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper, we assess the safety of ICI administration in cancer patients during the coronavirus pandemic in order to guide the usage of these highly efficacious agents.
Search related documents:
Co phrase search for related documents- active cancer and lymphoma leukemia: 1, 2, 3, 4
- active cancer history and lymphoma leukemia: 1
- active chemotherapy and lung cancer: 1, 2, 3
- active chemotherapy and lymphoma leukemia: 1, 2
- active therapy and lung cancer: 1, 2, 3, 4, 5, 6, 7
- active therapy and lymphoma leukemia: 1
- adapt strategy and low remain: 1
- adrenal insufficiency and lung cancer: 1
- low remain and lung cancer: 1, 2, 3
- lung cancer and lymphoma leukemia: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date